JAGX Jaguar Health, Inc.
Price Chart
Executive Summary
Jaguar Health received formal notice from Nasdaq on May 26, 2026 that it has regained compliance with the $1.00 bid price rule, removing immediate delisting risk. However, the Nasdaq Hearings Panel will maintain jurisdiction until September 1, 2026, and the company is subject to a Mandatory Panel Monitor through May 26, 2027, during which any 30-consecutive-business-day bid price failure would trigger a delist determination without the standard 180-day grace period.
Actionable Insight
The immediate delisting threat is resolved, but the one-year Mandatory Panel Monitor with no 180-day grace period means the stock must consistently trade above $1.00. Monitor daily closing bid prices closely — any sustained dip below $1.00 for 30 consecutive days would trigger a delist determination. The revenue growth cited (816% YoY) is from a prior press release and reflects a low-base effect from the Future Pak out-license; watch for the Q1 2026 10-Q for absolute revenue and cash runway details.
Key Facts
- Jaguar regained compliance with Nasdaq Listing Rule 5550(a)(2) (Bid Price Rule) as of May 26, 2026.
- Nasdaq Hearings Panel retains jurisdiction over the listing until September 1, 2026.
- Company is subject to a Mandatory Panel Monitor for one year through May 26, 2027.
- During the monitoring period, a failure to maintain a $1.00 closing bid price for 30 consecutive business days will result in a delist determination without the standard 180-day grace period.
- CEO Lisa Conte cited Q1 2026 net revenue increased 816% vs Q1 2025 and 527% vs Q4 2025, driven by the Future Pak out-license agreement for Mytesi and Canalevia-CA1.
- Company is targeting an NDA submission in mid-2027 for its crofelemer powder-for-oral-solution formulation for rare intestinal failure indications.
Financial Impact
No direct financial impact from the compliance notice itself; the company reported Q1 2026 net revenue growth of 816% YoY and 527% QoQ, but no absolute dollar figures were provided in this filing.
Risk Factors
- Mandatory Panel Monitor through May 26, 2027 — any 30-day bid price failure triggers delist process without standard grace period.
- Panel retains jurisdiction until September 1, 2026, allowing potential additional conditions.
- Revenue growth is from a licensing deal with Future Pak; sustainability and cash generation remain unproven.
- Pre-revenue for the lead pipeline candidate (crofelemer) with NDA target in mid-2027 — no near-term product revenue.
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-240645 |
| Document: d129501dex991.htm | 0001193125-26-240645 |
| Document: 0001193125-26-240645-index-headers.html | 0001193125-26-240645 |
| Document: 0001193125-26-240645-index.html | 0001193125-26-240645 |
| Document: 0001193125-26-240645.txt | 0001193125-26-240645 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 2, 2026
3d ago
|
8-K
| $2.92 $3.05 | ▼ −4.45% | ▼ −4.05% | $2.80 (+4.11%) |
|
May 29, 2026
7d ago
|
DEFA14A
| — | awaiting T+1 | — | — |
|
May 27, 2026
9d ago
|
8-K
| $3.19 $3.29 | ▲ +3.13% | ▲ +2.58% | $2.80 (−12.23%) |
|
May 22, 2026
14d ago
|
8-K
| — | awaiting T+1 | — | — |
|
May 19, 2026
17d ago
|
8-K
| — | awaiting T+1 | — | — |
|
May 6, 2026
4w ago
|
DEFA14A
| $2.82 $2.98 | ▲ +5.67% | ▲ +6.00% | $2.80 (−0.71%) |
|
May 4, 2026
4w ago
|
8-K
| $3.25 $3.01 | ▲ +7.38% | ▲ +8.18% | $2.80 (+13.85%) |
|
Apr 27, 2026
5w ago
|
8-K
| $9.80 $0.2410 | ▲ +97.54% | ▲ +97.06% | $2.80 (+71.43%) |
|
Apr 21, 2026
6w ago
|
8-K
| $14.25 $0.4100 | ▼ −97.12% | ▼ −98.14% | $2.80 (−80.34%) |
|
Apr 7, 2026
8w ago
|
8-K
| $14.35 $0.3990 | ▲ +97.22% | ▲ +99.76% | $2.80 (+80.49%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access